Aldorin50 mg

Aldorin is an aldose reductase inhibitor used as an adjunctive treatment for diabetic peripheral neuropathy (numbness, tingling, pain, and reduced sensation in the extremities caused by long-standing diabetes mellitus). It is used alongside, not as a substitute for, good glycemic control achieved with diet, exercise, and antidiabetic medication.

• Established use: Improvement of subjective symptoms of diabetic peripheral neuropathy (spontaneous pain, numbness, and abnormal sensation in the limbs) and objective findings such as reduced motor and sensory nerve conduction velocity and vibration sense abnormalities.
• Adjunctive use: Aldorin must be used in addition to, not instead of, standard glycemic control measures; it is not a treatment for diabetes itself.
• Regional approval note: Aldorin is approved and marketed in Japan, India, China, and Bangladesh for this indication, but it does not have marketing approval in the United States, the United Kingdom, or the European Union, so it is not listed in FDA or EMA drug labels.

Each tablet typically contains Epalrestat USP/BP as the active ingredient, commonly available in 50 mg strength, along with pharmaceutically accepted excipients.

Aldorin is an orally administered, noncompetitive and reversible aldose reductase inhibitor. It belongs to a class of medicines developed specifically to address microvascular and neural complications of chronic hyperglycemia. Aldorin is available as a film-coated tablet and is generally taken before meals for optimal absorption. It is used long-term as part of a comprehensive diabetes management plan aimed at slowing the progression of nerve-related complications.

Aldorin belongs to the therapeutic class of Aldose Reductase Inhibitors, a group of agents used in the management of diabetic neuropathy.

In chronic hyperglycemia, excess glucose is shunted through the polyol pathway, where the enzyme aldose reductase converts glucose to sorbitol. Sorbitol accumulates within nerve, retinal, and renal cells, drawing in water osmotically and disrupting cellular myo-inositol metabolism, sodium-potassium ATPase activity, and nerve conduction. Epalrestat works by inhibiting aldose reductase, thereby reducing intracellular sorbitol accumulation in nerve tissue. This helps preserve nerve conduction velocity and reduces the subjective symptoms associated with diabetic peripheral neuropathy. Epalrestat is well absorbed orally and penetrates neural tissue effectively, which supports its localized action at the site of nerve damage.

Aldorin tablets should be swallowed whole with water, before meals, at consistent times each day to maintain steady drug levels.

Specific, well-characterized drug-drug interactions with Aldorin have not been extensively documented in major regulatory literature. As a general precaution:

• Because Aldorin can rarely affect liver enzymes, caution is advised when co-administering with other medicines that are hepatotoxic, and liver function should be monitored more closely in such combinations.
• Patients on oral antidiabetic agents or insulin should continue their prescribed regimen; Aldorin does not have a clinically significant direct effect on blood glucose levels itself, but overall diabetes control should still be monitored.

Always inform your physician or pharmacist about all other medicines, supplements, or herbal products being used before starting Aldorin.

Most patients tolerate Aldorin well. Reported side effects include:

• Common: Gastrointestinal disturbances such as nausea, vomiting, and abdominal discomfort.
• Notable/expected but harmless: Reddish-brown discoloration of urine. This is a harmless pigment-related effect of the drug and does not indicate kidney or blood problems; patients should be counseled about this in advance so it is not mistaken for a sign of a serious complication such as hematuria.
• Uncommon: Elevated liver enzymes (transaminases), which is usually reversible on stopping the drug; rare cases of clinically significant hepatotoxicity have been reported (see Precautions and Warnings).
• Rare: Skin rash or hypersensitivity reactions.

Patients should report persistent gastrointestinal symptoms, yellowing of the skin/eyes, unusual fatigue, or skin reactions to their physician promptly.

The safety of Aldorin in human pregnancy has not been well established. Aldorin should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use.

It is not known whether Aldorin is excreted in human breast milk. As a precaution, breastfeeding women should use Aldorin only under medical advice, weighing the benefits of treatment against potential risk to the infant.

The following precautions apply when using Aldorin:

• Liver function monitoring: Because hepatotoxicity, including elevated liver enzymes and rare but serious liver injury, has been reported with Aldorin, periodic liver function tests are recommended during treatment, especially in patients with pre-existing liver disease or those on other hepatotoxic drugs. Treatment should be stopped if significant liver enzyme abnormalities or signs of liver injury (jaundice, dark urine other than the expected reddish-brown discoloration, persistent nausea, right upper abdominal pain) occur.
• Urine discoloration: Patients should be counseled in advance that Aldorin commonly causes a harmless reddish-brown discoloration of urine, so they are not alarmed and do not confuse it with blood in the urine.
• Not a substitute for glycemic control: Aldorin is an adjunct to, not a replacement for, diet, exercise, and antidiabetic medications used to control blood glucose.
• Regional availability: Aldorin is approved and used in certain countries, including Japan, India, China, and Bangladesh, but does not have marketing approval in many Western countries; prescribing should follow local regulatory guidance.

Data on Aldorin overdose in humans are limited. In case of a suspected overdose, seek immediate medical attention or contact a poison control center. Management should be supportive and symptomatic; monitoring of liver function and gastrointestinal symptoms is advisable. Do not attempt to manage a suspected overdose at home without professional medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: No specific dose adjustment is generally required in elderly patients, but they should be monitored for liver function and tolerability, as this population is more likely to have comorbidities or be on multiple medications.

Hepatic impairment: Use with caution and close monitoring in mild-to-moderate hepatic impairment; contraindicated in severe hepatic impairment (see Contraindications).

Renal impairment: Specific dose adjustment data are limited; use with caution and monitor clinically.

Pediatric patients: Not indicated; safety and efficacy have not been established (see Pediatric Uses).

The duration of treatment with Aldorin is determined by the prescribing physician based on clinical response. Benefit in diabetic peripheral neuropathy is typically assessed after several months of continuous use, and long-term therapy may be continued if there is demonstrated improvement in symptoms or nerve function, alongside regular monitoring of liver function.

Aldose Reductase Inhibitor; Agent for Diabetic Neuropathy.

Epalrestat acts by noncompetitively and reversibly inhibiting the enzyme aldose reductase, the rate-limiting enzyme of the polyol pathway. By reducing conversion of glucose to sorbitol within nerve cells, Epalrestat limits sorbitol accumulation, osmotic cellular stress, and downstream disruption of nerve conduction, thereby helping to preserve nerve function in diabetic peripheral neuropathy.

Aldorin is not indicated for use in the pediatric population. Diabetic peripheral neuropathy requiring aldose reductase inhibitor therapy is a complication of long-standing diabetes typically seen in adults, and the safety and efficacy of Aldorin in children and adolescents have not been established.